Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter's Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Technological advancements
4.1.2 Increased prevalence of chronic diseases
4.1.3 Need for controlled drug release
4.1.4 Rise in individual therapy
4.1.5 Increased understanding about drug metabolism among the population
4.2 Restraints
4.2.1 Recall of the products
4.2.2 strict regulatory framework
4.2.3 Injuries and infections fear while usage
4.3 Opportunities
4.3.1 Increasing demand for biosimilars and generic drugs
4.3.2 Focus on overcoming unmet medical needs
4.3.3 Self-administration and home care
4.3.4 Emerging markets
4.4 Challenges
4.4.1 High cost of development
4.4.2 Patent cliff and patent expiry
Chapter 5 North America Drug Delivery Devices Market– By Mode of Delivery
5.1 Nasal
5.1.1 Nasal inhalers
5.1.2 Nasal sprays
5.1.3 Nasal drops
5.1.4 Others
5.2 Oral
5.2.1 By mode of action
5.2.1.1 Hydrodynamic pressure controlled system
5.2.1.2 Slow dissolving salts & complexes
5.2.1.3 Ion - exchange resin drug complexes
5.2.1.4 Ph - independent formulations
5.2.1.5 Osmotic pressure controlled systems
5.2.1.6 Diffusion controlled systems
5.2.1.7 Dissolution controlled systems
5.3 Ocular
5.3.1 Ointments & gels
5.3.2 Eye drops
5.3.3 Others
5.4 Implantable
5.4.1 Intravitreal implants
5.4.2 Brachytherapy seeds
5.4.3 Contraceptives
5.4.4 Drug-eluting stents
5.5 Injectable
5.5.1 Conventional drug delivery
5.5.2 Self-Injected drug delivery
5.5.2.1 Prefilled syringes
5.5.2.2 Injectable pen
5.5.2.3 Autoinjectors
5.5.2.4 Needle-free injectors
5.5.2.5 Self Flushing infusion bag
5.6 Transdermal
5.6.1 By mode of administration
5.6.1.1 Microscopic injections
5.6.1.2 Ultrasound
5.6.1.3 Electroporation
5.6.1.4 Iontophoresis
5.6.2 By type of patches
5.6.2.1 Vapour patch
5.6.2.2 Matrix
5.6.2.3 Reservoir
5.6.2.4 Multilayer drug in adhesive
5.6.2.5 Single layer drug in adhesive
5.6.3 Transdermal Gels
5.7 Topical
5.7.1 Semi-solid formulations
5.7.2 Liquid formulations
5.7.3 Solid formulations
5.8 Pulmonary
5.8.1 By mode of administration
5.8.1.1 Nebulizer
5.8.1.2 Dry powder inhalers
5.8.1.3 Metered dose inhalers
5.9 Rectal
5.10 Others
Chapter 6 North America Drug Delivery Devices Market- By End-Users
6.1 Hospitals
6.2 Ambulatory Surgical Centers/Clinics
6.3Home Care Settings
6.4 Diagnostic Centers
6.5 Others
Chapter 7 North America Drug Delivery Devices Market- By Geography
7.1 Introduction
7.2 U.S.
7.3 Canada
7.4 Mexico
Chapter 8 North America Drug Delivery Devices Market- Company Profiles
8.1 Abbott Laboratories
8.2 B. Braun Melsungen AG
8.3 Pfizer, Inc.
8.4 F. Hoffmann-La Roche Ltd.
8.5 Baxter International Inc.
8.6 Smith Medical
8.7 3M Company
8.8 Johnson & Johnson Services, Inc.
8.9 Novartis AG
8.10 Sanofi Pharmaceutical company
8.11 Bayer AG
8.12 Antares Pharma, Inc.
8.13 Becton, Dickinson and Company
8.14 GlaxoSmithKline PLC
8.15 Merck & Co., Inc.
Chapter 9 North America Drug Delivery Devices Market- Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 10 Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
Chapter 11 Appendix
11.1 List of Tables
11.2 List of Figures
